Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structural requirements for ErbB2 transactivation.
Penuel E, Schaefer G, Akita RW, Sliwkowski MX. Penuel E, et al. Among authors: schaefer g. Semin Oncol. 2001 Dec;28(6 Suppl 18):36-42. Semin Oncol. 2001. PMID: 11774204 Review.
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. Schaefer G, et al. Cancer Cell. 2011 Oct 18;20(4):472-86. doi: 10.1016/j.ccr.2011.09.003. Cancer Cell. 2011. PMID: 22014573 Free article.
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, Crocker L, Schaefer G, Sliwkowski MX, Damico-Beyer LA. Kamath AV, et al. Among authors: schaefer g. Cancer Chemother Pharmacol. 2012 Apr;69(4):1063-9. doi: 10.1007/s00280-011-1806-6. Epub 2011 Dec 28. Cancer Chemother Pharmacol. 2012. PMID: 22203367
Oncogenic ERBB3 mutations in human cancers.
Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S. Jaiswal BS, et al. Among authors: schaefer g. Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Cancer Cell. 2013. PMID: 23680147 Free article.
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX. Phillips GD, et al. Among authors: schaefer g. Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4. Clin Cancer Res. 2014. PMID: 24097864 Clinical Trial.
High cell-surface density of HER2 deforms cell membranes.
Chung I, Reichelt M, Shao L, Akita RW, Koeppen H, Rangell L, Schaefer G, Mellman I, Sliwkowski MX. Chung I, et al. Among authors: schaefer g. Nat Commun. 2016 Sep 7;7:12742. doi: 10.1038/ncomms12742. Nat Commun. 2016. PMID: 27599456 Free PMC article.
536 results